Join
Live feed
·
PRReleasevia Quantisnow
BeyondSpring Inc. logo

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

ByQuantisnow·Wall Street's wire, on your screen.
BYSI· BeyondSpring Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BYSI (BeyondSpring Inc.) and more on Quantisnow.